Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Mar;8(2):427-433.
doi: 10.1111/andr.12695. Epub 2019 Aug 21.

Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma

C Bisegna  1 , G L Gravina  2 , F Pierconti  3 , M Martini  3 , L Larocca  3 , P Rossi  1 , P Grimaldi  1 , S Dolci  1 , S Di Stasi  4 , E A Jannini  5
Affiliations
Free article

Regulation of PDE5 expression in normal prostate, benign prostatic hyperplasia, and adenocarcinoma

C Bisegna et al. Andrology. 2020 Mar.
Free article

Abstract

Background: Type 5 phosphodiesterase (PDE5) expression in the normal and pathological prostate is controversial.

Objectives: This study aimed at identifying the cell type/s, if any, expressing PDE5 in human healthy or pathological prostate sections in order to further validate the rationale of PDE5 inhibitor (PDE5i) treatment of benign prostatic hyperplasia (BPH) and their safety in the treatment of erectile dysfunction following prostate cancer (PCa) surgery.

Materials and methods: By immunohistochemical analysis, we studied PDE5 expression in tissue microarrays containing sections obtained from healthy, BPH, and PCa samples.

Results: Our results showed that PDE5 is barely expressed in the epithelial or stromal compartment of normal human prostates, but it is highly expressed in the stromal compartment of BPH sections. We also found that a low but significant number of PCa samples (22%) expressed PDE5 in the epithelial cancer cells but not in stromal cells and that such expression was not correlated with the tumor aggressiveness, according to their Gleason score.

Discussion and conclusion: PDE5 overexpression in the stromal compartment of BPH samples supports the rationale of PDE5 as a target in lower urinary tract symptoms of BPH. PDE5 expression in a significant percentage of PCa samples but the lack of correlation with the Gleason score suggests that this enzyme is not correlated with tumor aggressiveness; however, a role of PDE5 in the minimal residual disease of PCa cannot be excluded.

Keywords: Cancer; Human; Immunohistochemistry; PDE5 inhibitor; Phosphodiesterase; prostate.

PubMed Disclaimer

References

    1. Barone I, Giordano C, Bonofiglio D, Catalano S & Andò S. (2015) Phosphodiesterase type 5 as a candidate therapeutic target in cancers. Curr Pathobiol Rep 3, 193-201.
    1. Barone I, Giordano C, Bonofiglio D, Andò S & Catalano S. (2017) Phosphodiesterase type 5 and cancers: progress and challenges. Oncotarget 8, 99179-99202.
    1. Beavo JA. (1995) Cyclic nucleotide phosphodiesterases: functional implications of multiple isoforms. Physiol Rev 75, 725-748.
    1. Blander DS, Sanchez-Ortiz RF, Wein AJ & Broderick GA. (2000) Efficacy of sildenafil in erectile dysfunction after radical prostatectomy. Int J Impot Res 12, 165-168.
    1. Briganti A & Montorsi F. (2006) Penile rehabilitation after radical prostatectomy. Nat Clin Pract Urol 3, 400-401.

Publication types

Substances

LinkOut - more resources